[Form 4] Kura Oncology, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Troy Edward Wilson, President, CEO and a director of Kura Oncology, purchased additional common stock on 08/12/2025 and 08/13/2025. On 08/12/2025 he acquired 36,506 shares at a weighted average price of $5.8505. On 08/13/2025 he acquired 13,494 shares at a weighted average price of $6.6417. Following these purchases the reporting person directly beneficially owns 50,968 shares. The filing discloses indirect holdings of 279,194 shares held by the One Fish Two Fish Revocable Trust and 300,000 shares held by the Lorax Charitable Remainder Unitrust. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 08/13/2025. Explanatory notes state the trades were executed in multiple fills and include 409 shares previously acquired on 05/17/2024 under the issuer's Employee Stock Purchase Plan.

Positive

• Insider purchases totaling 50,000+ shares over two days, increasing direct beneficial ownership to 50,968 shares
• Clear disclosure of indirect holdings: 279,194 shares (One Fish Two Fish Revocable Trust) and 300,000 shares (Lorax Charitable Remainder Unitrust)
• Transaction details provided with weighted average prices and an offer to supply fill-level information on request

Negative

• None.

Insights

Financial Analyst

TL;DR: The CEO and director increased direct holdings by 50,000+ shares across two days and maintains substantial indirect holdings totaling 579,194 shares.

The filings show material insider purchases: 36,506 shares on 08/12/2025 at a weighted average of $5.8505 and 13,494 shares on 08/13/2025 at $6.6417, bringing direct beneficial ownership to 50,968 shares. Indirect positions are explicitly disclosed: 279,194 shares via One Fish Two Fish Revocable Trust and 300,000 shares via Lorax Charitable Remainder Unitrust. The report was filed by one reporting person and executed by an attorney-in-fact. All transaction prices are presented as weighted averages and multiple fills are disclosed; the filer offers to provide fill-level details upon request.

Corporate Governance Expert

TL;DR: The insider disclosed open-market purchases and clear direct and indirect ownership structures, with formal filing and attestations in place.

The Form 4 identifies the reporting person as President and CEO and a director, and shows contemporaneous purchases over two days that increased direct ownership to 50,968 shares. The filing documents trust and unitrust holdings separately, indicating layered beneficial ownership. The disclosure includes compliance elements: Form filed by one reporting person, weighted-average pricing disclosures for multiple trades, and signature by an attorney-in-fact dated 08/13/2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WILSON TROY EDWARD

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

12730 HIGH BLUFF DRIVE, SUITE 400

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2025		P		36,506	A	$5.8505(1)	37,474(2)	D
Common Stock	08/13/2025		P		13,494	A	$6.6417(3)	50,968	D
Common Stock								279,194	I	by One Fish Two Fish Revocable Trust
Common Stock								300,000	I	by Lorax Charitable Remainder Unitrust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $5.56 to $5.995. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

2. Includes 409 shares acquired on May 17, 2024 pursuant to the Issuer's Employee Stock Purchase Plan.

3. This transaction was executed in multiple trades at prices ranging from $6.485 to $6.735. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

	Teresa Bair, Attorney-in-fact for Troy E. Wilson	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did KURA's President and CEO report on this Form 4?

The reporting person purchased 36,506 shares on 08/12/2025 at a weighted average price of $5.8505 and 13,494 shares on 08/13/2025 at a weighted average price of $6.6417.

How many KURA shares does Troy E. Wilson beneficially own after these transactions?

Following the reported transactions the reporting person directly beneficially owns 50,968 shares.

Does the Form 4 disclose any indirect holdings for the reporting person?

Yes. The filing discloses 279,194 shares held by the One Fish Two Fish Revocable Trust and 300,000 shares held by the Lorax Charitable Remainder Unitrust.

Were the reported trades executed in single or multiple fills and are exact fill prices provided?

The explanation states the trades were executed in multiple fills; the Form reports weighted average prices and offers to provide full fill-level details upon request.

Who signed the Form 4 and when was it signed?

The Form was signed by Teresa Bair, Attorney-in-fact for Troy E. Wilson, on 08/13/2025.